Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 5/20 | 0.53 |
| ▸ | TAS2R14 | Q9NYV8 | 4/20 | 0.51 |
| ▸ | CA12 | O43570 | 2/20 | 0.51 |
| ▸ | CA1 | P00915 | 2/20 | 0.51 |
| ▸ | CA2 | P00918 | 2/20 | 0.51 |
| ▸ | CA4 | P22748 | 2/20 | 0.51 |
| ▸ | CA9 | Q16790 | 2/20 | 0.51 |
| ▸ | MMP9 | P14780 | 1/20 | 0.46 |
| ▸ | MMP13 | P45452 | 1/20 | 0.46 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.46 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4905775 | 0.94 | TAS2R14 (0.58) | CNR2TAS2R14CA12CA1CA2 | |
| SCHEMBL4908668 | 0.92 | TAS2R14 (0.49) | CNR2TAS2R14CA12CA1CA2 | |
| SCHEMBL4900641 | 0.92 | MEN1 (0.54) | CNR2TAS2R14CA12CA1CA2 | |
| SCHEMBL4898092 | 0.91 | TAS2R14 (0.48) | CNR2TAS2R14CA12CA1CA2 | |
| SCHEMBL4908413 | 0.90 | CNR2 (0.48) | CNR2TAS2R14CA12CA1CA2 | |
| SCHEMBL4894471 | 0.90 | CA12 (0.48) | TAS2R14CA12CA1CA2CA4 | |
| SCHEMBL4906541 | 0.88 | TAS2R14 (0.46) | CNR2TAS2R14CA12CA1CA2 | |
| SCHEMBL4897933 | 0.87 | TAS2R14 (0.46) | CNR2TAS2R14CA12CA1CA2 | |
| SCHEMBL4895626 | 0.86 | TAS2R14 (0.56) | CNR2TAS2R14CA12CA1CA2 | |
| SCHEMBL4902732 | 0.83 | KMT2A (0.48) | TAS2R14CA12CA1CA2CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080090829-A1 | SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS | PFIZER INC. | 2008-04-17 | — | — | US | disclosed |
| US-20080090829-A1 | SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS | PFIZER INC. | 2008-04-17 | — | — | US | disclosed |
| US-20080090829-A1 | SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS | PFIZER INC. | 2008-04-17 | — | — | US | disclosed |
| US-20060229363-A1 | Substituted Heteroaryl- and Phenylsulfamoyl Compounds | HAMANAKA ERNEST S | 2006-10-12 | — | — | US | disclosed |
| US-20050288340-A1 | Substituted heteroaryl- and phenylsulfamoyl compounds | PFIZER INC | 2005-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060229363-A1 | Substituted Heteroaryl- and Phenylsulfamoyl Compounds | PPARA, PPARG, PPARD | CNR2 534/4885TAS2R14 4063/4885CA12 4882/4885 |
| US-20050288340-A1 | Substituted heteroaryl- and phenylsulfamoyl compounds | PPARA, PPARG, PPARD | CNR2 644/4885TAS2R14 4032/4885CA12 4883/4885 |
| US-20080090829-A1 | SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS | PPARA, PPARG, PPARD | CNR2 644/4885TAS2R14 4032/4885CA12 4883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.